Protein Interactions Group,
Cancer and Inflammation Program,
Center for Cancer Research,
National Cancer Institute,
National Institutes of Health,
1050 Boyles Street,
Building 567 Room 180,
Frederick, MD 21702.
- antibody engineering
- vaccine development
- cancer immunotherapy
- Li Wei received his bachelor degree of applied chemistry in 2009 from Huazhong University of Science and Technology, China.
- Trained as a bioinorganic chemist in Institute of Biomedical Science (IBS), he earned his PhD in chemical biology from Fudan University, China in 2014.
- His PhD work focus on dissecting the underlying mechanisms of metalloproteins and metalloenzymes involved in key physiological and pathological bio-processes, which include redox-tuning metalloenzymes, metal ions homeostasis maintaining regulators and metalloproteins in neurodegenerative disease.
- In 2014, He joined Dr. Dimiter Dimitrov's group at National Cancer Institute, National Institutes of Health, U.S.A (NIH/NCI) for his postdoctoral training where he study on antibody engineering and vaccine development using combinations of methodologies involving display/screening/library, protein biochemistry, structural biology and computational biology as well as virology, immunology.
- His research field covers the development of useful antibody therapeutics and vaccines against cancer, HIV-1 and emerging and biodefense-related viruses; T Cell Receptor (TCR) engineering to targeting tumor associated antigens or specific antigens; Chimeric Antigen receptor (CAR) engineering; and bispecific antibody design and development.